- Home
- THFF vs HUMA Comparison
THFF vs HUMA Comparison
Compare THFF & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THFF | HUMA |
|---|---|---|
| Founded | 1984 | 2004 |
| Country | United States | United States |
| Employees | N/A | 220 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 796.4M | 229.7M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | THFF | HUMA |
|---|---|---|
| Price | $62.67 | $0.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $62.00 | $9.29 |
| AVG Volume (30 Days) | 52.8K | ★ 7.3M |
| Earning Date | 04-21-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | ★ 67.00 | N/A |
| EPS | ★ 6.68 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.86 | N/A |
| Revenue Next Year | $3.55 | $731.05 |
| P/E Ratio | $9.03 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.05 | $0.70 |
| 52 Week High | $69.21 | $3.32 |
Technical Indicators
Market Signals| Indicator | THFF | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 49.47 | 37.24 |
| Support Level | $51.00 | N/A |
| Resistance Level | $63.04 | $1.30 |
| Average True Range (ATR) | 1.62 | 0.10 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 55.55 | 24.45 |
Price Performance
Historical ComparisonAbout THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.